{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:52:26Z","timestamp":1788306746449,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.gastrohep.2020.10.004","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T11:04:02Z","timestamp":1604747042000},"page":"337-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease"],"prefix":"10.1016","volume":"44","author":[{"given":"Javier","family":"Lucas Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Su\u00e1rez Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Poza Cord\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"S\u00e1nchez Azofra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Rueda Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Martin Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Yebra Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Andaluz Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Dolores","family":"Mart\u00edn Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2020.10.004_bib0155","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0160","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0165","first-page":"276","article-title":"Addition of a immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab","volume":"45","author":"Ungar","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0170","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0175","doi-asserted-by":"crossref","unstructured":"Yarur AJ, Jain A, Sussman DA, Barkin JS, Quintero MA, Princen F, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: The ATLAS study. Gut. 2015. Epub ahead of print.","DOI":"10.1136\/gutjnl-2014-308099"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0180","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0185","first-page":"142","article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial","volume":"46","author":"Roblin","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0190","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial","volume":"10","author":"Matsumoto","year":"2016","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0195","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/ecco-jcc\/jjx181","article-title":"Thiopurines in inflammatory bowel disease: new findings and perspectives","volume":"12","author":"de Boer","year":"2018","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0200","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0205","first-page":"765","article-title":"Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays","volume":"36","author":"Vande Casteele","year":"2012","journal-title":"Pharmacol Ther Food"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0210","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0215","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/gastro\/gou087","article-title":"Optimizing the use of biological therapy in patients with inflammatory bowel disease","volume":"3","author":"Moss","year":"2015","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0220","first-page":"212","article-title":"Early drug and anti-infliximab antibody levels for prediction of primary non-response to infliximab therapy","volume":"47","author":"Bar-Yoseph","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0225","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cgh.2015.10.029","article-title":"Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis","volume":"14","author":"Brandse","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0230","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","article-title":"The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab","volume":"63","author":"Ungar","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0235","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","article-title":"A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease","volume":"23","author":"Brandse","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0240","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/MIB.0000000000000137","article-title":"Early infliximab trough levels are associated with persistent remission in paediatric patients with inflammatory bowel disease","volume":"20","author":"Singh","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0245","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/gutjnl-2014-307882","article-title":"Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial","volume":"65","author":"Baert","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0250","first-page":"30","article-title":"Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease \u2013 algorithm for practical management","volume":"43","author":"Ding","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0255","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","article-title":"Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial","volume":"63","author":"Cornillie","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0260","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease","volume":"64","author":"Vande Casteele","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0265","first-page":"529","article-title":"Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice","volume":"42","author":"Buurman","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0270","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ajg.2014.106","article-title":"Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial","volume":"109","author":"Steenholdt","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0275","first-page":"1128","article-title":"Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease","volume":"45","author":"Strik","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0280","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0285","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease","volume":"44","author":"Mackey","year":"2007","journal-title":"J Paediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0290","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease","volume":"104","author":"Marehbian","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0295","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/clpt.1987.4","article-title":"Thiopurine pharmacogenetics in leukaemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations","volume":"41","author":"Lennard","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2020.10.004_bib0300","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/bjh.14083","article-title":"Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: a population-based cohort study in Australia","volume":"174","author":"Na","year":"2016","journal-title":"Br J Haematol"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570520303873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570520303873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:44:29Z","timestamp":1759322669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570520303873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0210570520303873"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2020.10.004","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2020.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}